Background: One hundred sixty-eight peripheral T-cell lymphomas (PTCLs) were reviewed according to the Revised European-American Lymphoma (R.E.A.L.) Classification.
Introduction
Peripheral T-cell lymphomas (PTCLs) are quite common in Southern Japan and some parts of China, the USA and the Caribbean basin, where they have been extensively studied and often found to be related to HTLV-1 infection [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] .
In other geographic areas, including Western Countries, PTCLs represent about 10% of all lymphoid tumours and are not specifically associated with infectious agents [9] , although integration of the Epstein-Barr virus (EBV) has been found in some neoplasms, such as the nasal and angioimmunoblastic ones [13, 14] . During the past 10 years, extensive application of immunohistochemistry and molecular biology techniques has made the recognition of T-cell lymphomas (TCLs) much easier, but has not solved the uncertainties about their categorization . Thus, the usefulness of their separation from B-cell lymphomas, for instance, although accepted by most authors [16-18, 26, 31, 32] , is still disputed by others [33, 34] and in fact, TCLs are not specifically recognised by the Working Formulation [35] . The Updated Kiel Classification (UKC) [5, 9] distinguishes between low-and high-grade forms on the basis of histologic features, but the prognostic value of this subdivision remains uncertain [19, 20, 24, 36] . Furthermore, the UKC combines Japanese and Occidental cases, which in fact differ in terms of morphology, HTLV-1 integration and clinical manifestation, and catalogues pleomorphic PTCLs (small, medium, large) according to criteria found to be subjective in reproducibility studies [37] . Finally, there is substantial disagreement in the literature concerning the prognostic parameters to be applied to the study of PTCLsvarying as they do in cell size [4, 5, 9, 12] stage [36] and EBV integration [38] .
Following publication of the Revised EuropeanAmerican Lymphoma (R.E.A.L.) Classification [39] , we reviewed 168 examples of PTCL in order to assess the clinico-pathologic relevance of the categories proposed by this new approach.
Patients and methods

Case selection
The present series (168 cases) was selected from among 890 TCLs, which represented 9 2% of all non-Hodgkin's lymphomas treated at the Service of Pathologic Anatomy/Hematopathology Unit of Bologna University from January 1981 to June 1994. The selection criteria were: 1) case submission from one of the seven main centres which routinely refer patients to the Service (Institute of Haematology, Bologna University; Institute of Pediatric Oncology, Bologna University; Chair of Haematology, Udine University, Chair of Haematology, Parma University; Department of Haematology, Reggio Calabria Hospital; Department of Haematology, Pescara Hospital; Department of Haematology, Potenza Hospital), 2) availability of 3-um-thick tissue sections stained with H.&E., Giemsa, Gomori and immunostained for at least aT-cell-and a B-cell-associated antigen (see Table 1 ), 3) of non-lymphoblastic nature (except for the mycosis fungoid/Sezary syndrome categories), 4) adequate clinical information, with a followup period longer than one year, 5) HIV-negativity, and 6) treatment by second-or third-generation chemotherapy regimens, if of equivalent efficacy [40] . Twenty-six of 62 anaplastic large-cell lymphomas (ALCLs) of the present series corresponded to previously reported cases [41, 42] . Of the excluded cases, there were 158 precursor T-cell lymphomas, lymphoblastic, and 139 examples of the mycosis fungoid/ Sezary syndrome. The remaining 425 excluded cases represented patients lost to follow-up, or consultation biopsies from 53 different centers which lacked histological preparations for critical review (having been returned to the referring pathologist at the time of consultation), immunohistochemical analysis, or easily accessibility of clinical data. It should be pointed out that no significant differences were observed in terms of age and sex distribution between the enrolled and excluded cases.
Pathological material
Formalin-fixed, paraffin-embedded tissue blocks were available for 151 cases. New sections were cut from these blocks, picked up on Dako ChemMate slides and immunostained by the APAAP technique [43] and the antibodies listed in Table 1 . Antigen retrieval was performed as previously reported [44] , All tests were automatically carried out on a DakoTechMate 500 immunostainer.
Diagnostic criteria
The cases, which had originally been diagnosed according to the Kiel scheme [5, 9] , were reviewed on the basis of the R.E.A L. Classification [39] , With respect to the latter, the group of unspecified PTCLs was further subdivided into: medium (UM), mixed (UMX),. large (UL), and lympho-epithelioid (Lennert's) (Lei-) forms. In particular, the cases consisting of a mixture of lymphomatous elements of different sizes were classified as mixed; on the other hand, those with more than 50% of neoplastic cells showing uniform size were subdivided into medium and large subtypes according to the average diameter of the predominating elements (6-9 um and > 10 urn, respectively). The cellular size was assessed by an image-analysis computer program (SC Image DB, Image Data Base Version 2.0, developed by Studio Casti Imaging) in five randomly-chosen high-power fields (1,000-1,500 cells per case) in 3-um-thick Giemsa stained preparations, in accord with previous experience [45] . The Ki-67 values were estimated according to reported criteria [46] ; a distinction between cases with a proliferation rate higher or lower than 60% was also made following Chott et al. [22] , The histological and immunohistological preparations were independently reviewed by five of the authors (S.A., E.S., L.L., B.F., and S A P.). Consensus was regarded as the agreement among four of five observers, after individual evaluation of histological and immunohistological preparations and cell-size measurements. In case of the disagreement of two or more participants, the case was collectively discussed at a multi-head microscope, until a common diagnosis was reached.
Clinical information
Questionnaires were sent to seven of the above-mentioned institutions. The following data were collected: age, sex, stage, symptoms, bulky disease, mediastinal mass, extranodal involvement (bone marrow, liver, skin, lung), haemophagocytic syndrome, response to therapy, type of therapy employed, and survival. Complete response (CR) was defined as the total disappearance of signs and symptoms due to disease, as well as the normalisation of all previous anomalous findings Partial response (PR) was defined as the reduction of at least 50% of known disease, with the disappearance of the systemic manifestations, and no response (NR) as anything less than partial.
Statistical analysis
Survival and relapse-free survival (RFS) curves were calculated according to the method of Kaplan and Meier [47] The chi-square test was used whenever appropriate for comparison of groups or group variables. Two-sided P values were used throughout The prognostic factors -age, presence or absence of B symptoms, stage, serum lactate dehydrogenase (LDH), presence or absence of mediastinal disease, presence or absence of bulky disease, different histology (ALCL vs. non-ALCL) -were correlated with treatment outcome, defined as CR rate, according to Cox's linear logistic model [48] Cox's proportional hazards regression model was used to assess the effect of covariates on the RFS time [49] ,
Results
Histological findings
Histological types
The diagnoses of the 168 cases according to the R.E.A.L. and Updated Kiel Classifications are summarised in Table 2 .
The different observers noted discrepancies in only 15 cases, for which the final diagnoses were established during discussions at a multi-head microscope. The differential diagnoses of these 15 cases were of LeL, angioimmunoblastic lymphoma (AILD) or PTCL-UMX. The elements used to solve the problem were: 1) prevalent cellular component (epithelioid histio- Abbreviations' AILD -angioimmunoblastic; ALCL -anaplastic large cell lymphoma; CT -common type; HL -Hodgkin's-like; LHlympho-histiocytic; SEC -secondary; ATLL -adult T-cell lymphoma/leukaemia, LCAL -large-cell anaplastic lymphoma; Pleo-1 -pleomorphic large; Pleo-m -pleomorphic medium; Pleo-s -pleomorphic small; PTCL-UM -peripheral T-cell lymphoma unspecified, medium; PTCL-UMX -peripheral T-cell lymphoma unspecified, mixed; PTCL-UL -peripheral T-cell lymphoma unspecified, large, PTCL-ULeL -peripheral T-cell lymphoma unspecified, lympho-epithehoid lymphoma/Lennert's lymphoma; T-CLL -T-chronic lymphocytic leukaemia; T-Ib -T-immunoblastic; TzL -T-zone lymphoma.
cytes in LeL, lymphocytes in AILD and PTCL-UMX), 2) cellularity (loose in AILD, dense in LeL and PTCL-UMX), 3) follicular dendritic cell (FDC) pattern (diffuse meshwork in AILD), and 4) residual follicles (burnt-out in AILD).
Pattern of growth
Lymph node biopsies provided the diagnostic material for 147 of 168 patients, and in 69.1% they showed a diffuse effacement of the normal structure. In the remaining 30.9%, residual follicles provided with either florid or burnt-out germinal centres were observed. In ALCL, both of the common (CT) and Hodgkin's-like (HL) types, intrasinusal diffusion of neoplastic cells was always observed. While in ALCL-CT the infiltrate usually extended to the paracortex, which appeared largely and diffusely effaced, in the HL subtype it gave rise to nodular aggregates, most often partly or completely surrounded by collagen bands and almost exclusively consisting of lymphomatous elements, with a cohesive growth pattern.
Twenty-one cases were diagnosed on samples taken at extranodal sites: the nose (two angiocentric T-cell lymphomas, one PTCL-UL), larynx (one PTCL-UL), pleura (one PTCL-UL), bone (one ALCL), bone marrow (one PTCL-UM), liver (one hepato-splenic y5 lymphoma, one PTCL-UM), subcutis (two panniculitis-like T-cell lymphomas), tongue (one PTCL-UM), oesophagus (one PTCL-UM), stomach (one PTCL-UM), jejunum (two intestinal T-cell lymphomas), nose and skin (one PTCL-UM), bone marrow and skin (one PTCL-UM), bone marrow and liver (one PTCL-UM), bone marrow and spleen (one PTCL-UM), and bone marrow, liver and spleen (one T-CLL).
Cytological features of tumour cells
ALCL and T-cell neoplasms other than ALCL will be considered separately because of their different cytological features. The cytological features of ALCLs corresponded to those extensively described in previous reports [41, 42] . Neoplastic cells, all of large size and provided with prominent nucleoli, displayed variable cytoplasmic staining, which ranged from clear to greyish-violet at Giemsa (Figure 1 ). Some multinucleated Reed-Sternberg-like cells were seen in both the CT and HL forms. The three examples of ALCL secondary showed no specifically morphologic aspects.
PTCLs other than ALCL were characterised by variability in the cellular composition, size and shape. In all instances, a spectrum of elements ranging from small to large was observed, with the exception of the T-CLL case, which displayed a rather uniform population. This variability of the cellular size was more pronounced in the samples of PTCL-UMX, PTCL-ULeL, and AILD (Figures 2 and 3) . On the other hand, more than 50% of the cases diagnosed as PTCL-M and PTCL-L consisted of elements of the same size (see 'Patients and methods') ( Figures 4 and 5) . The shape of lymphomatous cells varied remarkably within the same case, the nuclear contours ranging from slightly indented, cerebriform or bean-like to jellyfish-or embryo-like. Nucleoli were prominent and often multiple in blastic forms, while hardly visible in the smaller ones. The cytoplasmic rim . Peripheral T-cell lymphoma unspecified, medium: More than 50% of the lymphomatous population correspond to uniformly medium-sized elements; a moderate amount of cytoplasm and some variability in the nuclear profiles can be appreciated (Giemsa, x600). was always evident and showed variable staining at Giemsa (from clear/watery to basophilic). A few ReedSternberg-like cells were scattered throughout. The pleomorphism of the neoplastic population appeared even more pronounced in the only example of ATLL of the present series. The number of mitotic figures varied from case to case and paralleled the Ki-67 marking (see below). Foci of necrosis were rarely encountered with the exception of PTCL angiocentric, where the invasion of vessels by neoplastic cells produced extensive ischaemic damage.
Reactive components
Variable amounts of eosinophils, plasma cells and histiocytes were admixed with the neoplastic population in all cases. This reactive component was more abundant in AILD and angiocentric cases. Some epithelioid elements were clearly observed: they represented the main cellular constituent in the examples of LeL, where they might obscure the lymphomatous population. Numerous high endothelium venules were usually found in the non-ALCL cases: they were prominent and showed an arborising pattern and thickened basement membranes in AILD lymphomas. In all of the subtypes of ALCL, Figure 5 . Peripheral T-cell lymphoma unspecified, large: the lymphomatous population is mainly made up of large cells with a wide rim of basophilic cytoplasm, roundish nuclear profiles and evident nucleoli (Giemsa, x800).
reactive cells (small lymphocytes, neutrophils, eosinophils, and macrophages) represented a minor component of the entire examined population, with the notable exception of the lympho-histiocytic one, in which histiocytes outnumbered the neoplastic elements, as previously described [50] .
Immunohistochemicalfindings
Significant differences in the phenotypic profile were observed between ALCL and non-ALCL cases. The main findings are summarised in Table 3 .
All ALCLs showed strong and homogeneous membrane-bound and/or dot-like CD30 positivity in all neoplastic cells (Figure 6a ). Membrane-bound and/or dotlike CD15 positivity was seen in a small minority of the neoplastic cells in 22.2% of the tumours, irrespective of the histological subtype. Furthermore, they all reacted with the anti-CD3 antibody: the number of stained cells, as well as the type of positivity (membrane-bound and/ or dot-like intracytoplasmic) varied from patient to patient (Table 3) .
Among PTCLs other than ALCL, 23 tumours revealed a few scattered CD30+ blastic elements (Figure Figure 6 . While all elements of an anaplastic large-cell lymphoma strongly express the CD30 molecule (a), only some of the blasts of a peripheral T-cell lymphoma unspecified, mixed react with the Ber-H2/ CD30 monoclonal antibody (b) (APAAP technique, Gill's haematoxylin counterstain, x300). 6b), while 13 cases showed a dissociation of T-cell markers (seven cases: CD3-, CD43+, CD45R0+, one case CD3-, CD43+, CD45R0-, one case CD3+, CD43+, CD45R0-, four cases CD3+, CD43-, CD45R0+) ( Figure 7 ) ( Table 3 ). The example of hepato-splenic y5 T-cell lymphoma was studied on frozen material at both the immunohistochemical and molecular levels and was found to be positive for the TCR5-1 monoclonal antibody (T Cell Science, Cambridge, MA) and to show clonal rearrangement of the genes encoding for the T-cell receptor y gene (data not shown). The anti-CD21 antibody revealed large irregularly shaped accumulations of follicular dendritic cells in most AILD cases. Finally, the averages of neoplastic elements expressing the proliferation-associated nuclear antigen Ki-67 varied according to histological category as follows: PTCL-UMX 36% (range: 5%-90%), PTCL-UM 20% (10%-40%), PTCL-UL 43% (10%-90%), PTCL-ULeL 
17% (10%-20%), PTCL-AILD 30% (20%-40%), PTCL-ALCL 40% (10%-90%).
Clinical findings and statistical analysis
More than 95% of the questionnaires were completed and returned. The main clinical findings are summarised in Tables 4 and 5 . In particular, statistically significant differences were observed between the ALCL and non-ALCL groups, in terms of bulky disease (52.3% vs. 11.3%) (P = 0.000), mediastinal mass (60.3% vs. 32%) (P = 0.004), and rates of disease-free survival (68.0% vs. 38.2%) (P = 0.0001). Among ALCLs, the clinical features of each histotype paralleled the ones of previous reports [41, 42, 50] . Eight of 33 ALCLs-CT occurred in children, of whom six achieved complete remissions, and two (25%) succumbed. Nine of 25 (34%) adult patients with ALCL-CT died of their disease.
Among PTCLs other than ALCL, an unusual M/F ratio and higher mean age were observed in the LeL and AILD series, respectively. In three instances of PTCL-UM, a haemophagocytic syndrome was observed: two of which had a rapidly fatal course, as previously described [52] . All of the rare histotypes (T-CLL, subcutaneous panniculitis-like lymphoma, hepato-splenic y5 lymphoma, angiocentric lymphoma, intestinal T-cell lymphoma, and ATLL) were characterised by rapid fatality.
Aggressive therapeutical protocols were applied in all cases: they corresponded to the LSA 2 -L 2 scheme in the 15 pediatric cases (eight ALCL-CT, three ALCL-LH, four PTCL-U), while more heterogeneous regimens were used in adults: MACOP-B, F-MACHOP, CHOPBleo, Promace-Cytabom, L20, and C-MOPP/ABVD/ CAD Hybrid.
At eight years the overall survival ( Figure 8 ) was 38% and the relapse-free survival 50% (Figure 9 ). Figure 10 shows the overall survival according to the main histological categories: no statistically significant differences Figure 10 . Overall survival curves drawn according to the main histotypes (ALCL: anaplastic large-cell lymphoma; Mixed: peripheral Figure 8 . The curve illustrates the overall survival in the 168 patients T-cell lymphoma unspecified, mixed; Medium, peripheral T-cell lymphoma unspecified, medium; Large: peripheral T-cell lymphoma unspecified, large; AILD: peripheral T-cell lymphoma angioimmunowith peripheral T-cell lymphoma of the present series.
-Mastic). Figure 9 . Relapse-free survival curve of the study population as a Figure   " °V era " survival curvcs of the P eri P heral Tce11 lymphomas wno l e of the present series, when subdivided into anaplastic (ALCL) and non-anaplastic (non-ALCL) forms.
were observed. Figure 11 illustrates the actuarial survival data of ALCL and non-ALCL cases (P = 0.0001). No significant differences in survival were observed among: a) PTCLs other than ALCL with and without CD30-positive cells, b) ALCL-CT and ALCL-HL, and c) pediatric and adult ALCLs. Furthermore, clinical behaviour was not influenced by the Ki-67 marking [46] at presentation. To evaluate whether any covariate prognostic factor could influence CR outcome, adjustment for prognostic factors was performed by linear logistic model. The risk of a lower CR rate was correlated to the presence of bulky disease (P -0.001), histologic group (non-ALCL) (P = 0.01), and advanced stage (III-IV) (P = 0.0002). To assess the influence of prognostic factors on RFS, a Cox proportional hazards regression model was applied using the same covariates. Bulky disease (P = 0.001) and histological group (non-ALCL) (P = 0.02) remained poor prognostic factors in terms of relapse-free expectancy. Unfortunately, we could calculate neither the dose intensity nor the International Prognostic Factor Index [51] , as the required data were not available for all patients, the cases having been collected over a 14-yearperiod.
Discussion
To the best of our knowledge, this paper reports on the largest series of PTCLs collected until now in Western countries and the first categorised according to the R.E.A.L. Classification [39] .
First, our data support the usefulness of the R.E.A.L. scheme [39] that rendered possible the definition of groups of tumours associated with distinct clinicopathologic features.
The separation of ALCL from the remaining PTCLs proved to be of statistical significance and practical value, as the former revealed a distinct presentationin terms of age, mediastinal mass, and bulky diseaseand a much better clinical course, as already reported by Nakamura et al. [11, 12] . In keeping with our previous observations [41, 42] the incidence of mediastinal bulky disease represented the major difference between the ALCLs-CT and -HL of the present series, with the phenotypic profile and clinical course being generally identical. It is noteworthy that the current study showed a relatively high incidence of ALCLs in childhood (11 of 62 cases), which probably reflects the enrollment of a broader population than in our previous reports, which were based on data obtained in the course of a national trial on high-grade malignant lymphomas in adults [41, 42] . These pediatric cases -whose inclusion in the present series did not significantly influence the global ALCL survival -merit comment: i) they indeed appeared to be more frequent than pediatric non-ALCL PTCLs (only four cases recorded out of 106), and ii) as reported in previous studies [53, 54] , showed a clinical course even more favourable than the corresponding tumours in adults (the disease-free survival at six years being 82%). In the light of two recent papers [55, 56] on the expression of the chimeric protein p80NPM/ALK in a subset of ALCLs with T-cell phenotype and more favourable clinical outcome, further studies are needed to clarify the real incidence of the t(2;5) in ALCLs according to histological subtype and age distribution; an extensive investigation on this topic is currently underway in our laboratories.
PTCLs other than ALCL usually occurred in middleaged to elderly patients, who more often presented in stage III-IV (68%) and not infrequently displayed B symptoms (45.4%), bone marrow (25.8%) and other extra-nodal site involvement (37.1%). These findings resemble those reported by others (e.g., stage IV: 45%-77%, bone marrow infiltration: 22%-54%) [18] [19] [20] [21] [22] [23] [24] 32] . In spite of the aggressive regimens employed -which should be equally effective [40] -PTCLs other than ALCL of the present series displayed a poor response to therapy with 25.8% of resistant cases and 53.6% of patients who died of their disease. These data are in line with those from the literature [11, 12, 18, [20] [21] [22] [23] [24] 31] and should reflect the true clinical behaviour of these tumours in light of the quite homogeneous selection criteria employed for the present study.
In our series, clinical outcome was not significantly influenced by the histological grade. In particular, when applying the Updated Kiel Classification [5, 9] , no discrepancies were observed between the low-and highgrade forms (death rate 52.6% vs. 60.2%). This observation is in keeping with the results of several authors [20, 24, 36] , but not with those reported by Nakamura et al., who found the distinction between low-and high-grade PTCLs clinically relevant [11, 12] . However, the latter authors included in their study -based on a Japanese population -a large number of HTLV-1 positive patients, who have a more aggressive natural history than that of the HTLV-1-negative cases usually observed in Western countries [39] .
In the course of the present study, special attention was focused on the clinical features of each histological subtype. In particular, among PTCLs other than ALCL, the AILD type showed the highest mean age, while LeL displayed the highest male/female ratio and the lowest incidence of B symptoms and marrow involvement. The tentative categorisation of PTCL-U proposed by the I.L.S.G. [39] according to cell size was found to distinguish among neoplasms, which differed on morphologic and clinical grounds (see, for instance, the higher rate of complete remissions in the PTCL-UMX group). In this respect, the employment of an image analysis computer program certainly contributed to the avoidance of subjective evaluations of the cell size and, thus, to facilitation of the consensus among the observers, which was definitely larger than in previous studies [37] . The fact that the different PTCL subtypes were characterized by distinct survival curves (Figure 10 ) strengthens the concept that among these tumours, the identification of specific entities more than the histological grade is critical. A similar assumption has recently been made by Siegert et al. for the Kiel Lymphoma Study Group, who stated that "AILD type T-cell lymphoma characteristically differs from other non-Hodgkin's lymphomas" and "it has to be borne in mind that very aggressive courses are observed in almost all patients so that an early precise diagnosis and intensive treatment are necessary" [57] .
Immunohistochemistry was found useful for confirming the morphologic interpretation and for solving the problems in the differential diagnosis. Thanks to the availability of reagents working in paraffin sections and of the new techniques of antigen retrieval [44] , significant results were achieved on routine samples. Completely different profiles were observed in ALCL and non-ALCL cases (Table 3) : this can further contribute to the distinction of these two groups of tumours. Regarding the expression of CD30 by a small minority of neoplastic cells in 23 PTCLs other than ALCL, it should be underscored that this finding did not affect their histological classification and clinical course, as already reported by Lennert and Feller [9] , who stated that among "pleomorphic, medium-sized and large T-cell lymphomas ... approximately 30% of cases show cells with features of activated cells, viz. expression of IL-2 receptors (CD25) and HLA-DR/DQ or CD30" [9] . This observation further strengthens the need to avoid the term 'Ki-l+/CD30+ lymphoma', as this refers to a phenotypic attribute shared by several neoplasms (such as ALCL, PTCL, follicle center lymphoma, Hodgkin's disease), easily distinguishable on morphological grounds [58] . Moreover, our immunohistochemical findings confirm that a) some PTCLs show dissociation in the expression of CD3, CD43 and CD45R0 [10, 11, 15, [27] [28] [29] [30] [31] , which therefore should always be investigated in parallel, and b) hyperplasia of follicular dendritic cells is often found in PTCL-AILD [59] . The high incidence of CD8+ PTCLs needs further investigation to determine whether this is fortuitous or represents a peculiar characteristic of the Italian population. With regard to Ki-67 staining, we could not reproduce the figures of Chott et al. [22] , who found that immunoreactivity in more than 60% of the neoplastic cells can predict a poor outcome. In fact, in our series, a poor prognosis was also observed in PTCLs, with a number of cycling cells below 25%.
In conclusion, the results of the present study appear to shed new light on the intriguing problem of PTCLs and to support the approach proposed by the R.E.A.L. Classification concerning the categorisation of these rare neoplasms.
